Predictive performance of parent-metabolite population pharmacokinetic models of (S)-ketamine in healthy volunteers.

Otto ME, Bergmann KR, Jacobs G, van Esdonk MJ

The recent repurposing of ketamine as treatment for pain and depression has increased the need for accurate population pharmacokinetic (PK) models to inform the design of new clinical trials. Therefore, the objectives of this study were to externally validate available PK models on (S)-(nor)ketamine concentrations with in-house data and to improve the best performing model when necessary.